Search results: (10000)
News Long-term results of alpha-1-antitrypsin deficiency treatment – RAPID program
RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of alpha-1-antitrypsin inhibitor in the treatment of chronic obstructive pulmonary disease (COPD) associated with its deficiency.
News Sport and Physical Activity Benefit Hemophiliacs
Sport and physical activity are beneficial for individuals with hemophilia. This statement was confirmed by a study conducted by German and British authors published in the journal Haemophilia.
News Efficacy of Romiplostim in Children with Persistent or Chronic ITP
The effect of the thrombopoietin receptor agonist romiplostim in adult patients with immune thrombocytopenia (ITP) is well known. Equally important, however, are data on its treatment in children — presented by a study whose results were published in the journal Lancet.
News Liposomal Pegylated Irinotecan in the Treatment of Pancreatic Tumors
Combined treatment with liposomal pegylated irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) significantly improves overall survival in patients with metastatic ductal carcinoma of the pancreas. Analysis of the NAPOLI clinical trial revealed prognostic markers for long-term survival in patients treated this way.
News Irritable Bowel Syndrome and Non-specific Inflammatory Bowel Diseases Are Not Evolutionarily Related Diseases
The authors of the presented work attempted to compare the geographical distribution of irritable bowel syndrome and non-specific inflammatory bowel diseases and other factors related to these two diseases to reveal their potential evolutionary connection.
News Genetic Testing in Non-Small Cell Lung Cancer - Clinical Practice Experience
Targeted therapy has brought significant improvements to certain groups of patients with non-small cell lung cancer (NSCLC). Selecting patients who will benefit from targeted therapy can be performed using molecular profiling with next-generation sequencing (NGS) techniques. However, we still lack sufficient data on the feasibility and results of such profiling in real-world clinical practice, which was the focus of an analysis recently published in The Oncologist.
News Comparison of the effects of fibrinogen concentrates and fresh frozen plasma in patients with acute traumatic coagulopathy
A quasi-experimental study compared the effectiveness of fibrinogen concentrates and fresh frozen plasma in patients with severe blunt trauma requiring the administration of erythrocyte replacements.
News Nonacog Beta Pegol (N9-GP) in Bleeding Prophylaxis in Patients with Hemophilia B – Real World Data
The goal of hemophilia B treatment is currently the prevention of bleeding by administering a coagulation factor IX concentrate. The study presented below brings recent real-world data on treatment outcomes when switching to the latest preparation, nonacog beta pegol (N9-GP).
News Results of ATTUNE Total Knee Replacement Implantation – Data from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man
The ATTUNE knee replacement system was fully introduced into clinical practice in 2013. Since then, tens of thousands of implants have been administered to patients worldwide. The mid-term results are very positive, as evidenced by data from the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man.
News International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with bleeding disorders were published on the World Federation of Hemophilia (WFH) website. We present a basic summary of 13 points of this consensus. The original English version is available via the web link cited at the end of the article.
News Maintenance treatment with oral olaparib in women with BRCA1/2 mutation and relapsed ovarian cancer
In a phase III study published in the journal Lancet Oncology, data on the effectiveness of olaparib in patients with ovarian cancer and BRCA1/2 mutation were evaluated. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib had previously demonstrated effectiveness in a phase II study in patients with prior sensitivity to platinum-based treatments.
News The role of the physiotherapist in hemophilia care is expanding and irreplaceable − what it entails and how it changes with treatment advances?
In the team cooperation in caring for patients with hemophilia, the physiotherapist plays a very important role, which is expanding with today's comprehensive approach to treating this condition. The reason is that even in the era of modern treatment availability, many hemophilia patients have various musculoskeletal complications. A team of authors, preferentially physiotherapists, recently published a paper pondering whether the advent of new drugs will also change the position of physiotherapy in the care of patients with hemophilia.
News Manual Fascial Therapy in Patients with Hemophilic Arthropathy
Fascial therapy is a rehabilitative technique that mobilizes the fascial complex using manual techniques with the goal of improving tissue mobility and function, as well as influencing pain. A team of experts from Spain evaluated the safety of this method in hemophiliacs with developed arthropathy in their study.
News Safety Analysis of Baricitinib in Long-Term Treatment of Rheumatoid Arthritis
Janus kinase inhibitors are relatively new and very promising drugs, but their novelty also raises the question: Are they really safe? A brand-new analysis provides the answer by examining a cohort of patients treated for the longest duration to date.
News Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum FVIII levels > 1%. However, it has been shown that this goal may not protect many hemophiliacs from bleeding episodes. So how does prophylaxis that maintains higher FVIII levels stand? These insights were brought by the PROPEL study, whose results were recently published in Blood magazine.
News An Introductory Word to the Section on Hereditary Angioedema — MUDr. Roman Hakl, Ph.D.
Hereditary angioedema (HAE) is a genetically conditioned disease, currently classified into HAE with C1 inhibitor deficiency (HAE-C1-INH), referred to as HAE-I and HAE-II, and HAE with normal level and function of C1 inhibitor (HAE nC1-INH), also referred to as HAE-III (1).
News Digital Technology in COPD Therapy: Current Options and Future Prospects
This year, digital technologies have demonstrated their advantages in interpersonal communication, administrative processes, and in the field of medicine. The global crisis triggered by the coronavirus pandemic revealed the need to implement telemedicine into everyday medical practice. What are its options and future prospects in the therapy of patients with chronic obstructive pulmonary disease? These questions are thoroughly addressed in an article published in the Journal of Thoracic Disease last fall.
News Mental Health During the Pandemic − and How to Alleviate Its Impacts
At the symposium during the XV Spring Interactive Conference of the General Medical Society of ČLS JEP, which was eventually held in September 2021 in Prague, Prof. MUDr. Cyril Höschl, DrSc., FRCPsych, presented his lecture on the impacts of the COVID-19 pandemic on mental health. At the end of his speech, he also addressed the practical issue of selecting a suitable antidepressant.
News Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis
Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it essential and relevant to monitor its safety profile in clinical practice. The analysis of data collected over 8.4 years presented below provides current insights.
News Administration of Romiplostim in Patients with ITP in Real-World Practice in Central Europe
Data from the PLATON study on the administration of romiplostim in real-world clinical practice in Central and Eastern Europe confirmed very good efficacy in patients with newly diagnosed, persistent, and chronic ITP.
News How to Care for Dialysis Patients in the Times of COVID-19
More than 2 million people worldwide undergo maintenance hemodialysis in outpatient centers. Effective prevention of the spread of infection caused by the SARS-CoV-2 coronavirus within the care provided by hemodialysis centers is essential for the smooth provision of dialysis to patients with end-stage renal disease. The following work from experts in Boston is based on their experiences as well as recommendations from the American Society of Nephrology (ASN) and the Centers for Disease Control and Prevention (CDC).
News Safety and Efficacy of Different Antithrombotic Regimens in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention
Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI) require antithrombotic therapy for the prevention of atherothrombosis, stent thrombosis, and cerebrovascular stroke (CVS). The meta-analysis presented below attempted to clarify which antithrombotic regimen is most suitable in terms of safety and efficacy for these patients.
News Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children – Results of the TERIKIDS Study
Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.